Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy
Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy
复制标题
DOI：
10.1038/sj.bmt.1701670
复制
发表时间：
1999-05-01
影响因子：
4.8
通讯作者：
Glaspy, JA
中科院分区：
文献类型：
--
作者：
Glaspy, JA
近年来，人们越来越关注如何提高外周血祖细胞（PBPC）采集过程中获得的CD 34（+）细胞数量，以支持大剂量化疗。这些策略包括使用化疗加细胞因子进行动员，以及开发更有效的动员细胞因子组合，如干细胞因子加非格司亭。尽管这些策略的实施存在成本，但也可以从提高的PBPC产量中实现可预测的成本节约。现有数据表明，这些成本节约包括：每次防止单采2000美元，每次防止备用骨髓收获6000美元，每次防止再动员和单采阶段至少10 200美元。此外，有新的证据表明，最佳剂量（大于或等于5 x 10（6）/kg）与可接受但次佳（>1 x 10（6）/kg，但
There has been increasing interest in the de development of strategies to enhance the number of CD34(+) cells obtained during harvesting of peripheral blood progenitor cells (PBPC) to support high-dose chemotherapy. The strategies have included the use of chemotherapy plus cytokine for mobilization, and the development of more effective mobilizing cytokine combinations, such as stem cell factor plus filgrastim, Although there are costs associated with the implementation of these strategies, there are also predictable cost savings to be realized from the enhanced PBPC yields, Available data suggest that these cost savings include: $2000 per apheresis prevented, $6000 per back-up bone marrow harvest prevented, and at least $10 200 per remobilization and apheresis stage prevented. In addition, there is emerging evidence that the administration of optimal (greater than or equal to 5 x 10(6)/kg) as opposed to acceptable but suboptimal (>1 x 10(6)/kg but